Recent news on Fludara

`Playing God,' UK Denies Cancer Drugs, Patients Say (Update2)  -  May 17, 2007
Bloomberg...s Taxol for early breast cancer and Bayer AG's Fludara for a type of leukemia. The agency also has issued preliminary opinions that the NHS shouldn't fund

Expanded Label Filed for Campath®  -  Apr 9, 2007
Cancer Consultants (press release),...treatment of patients with B-CLL who have received prior therapy with an alkylating agent and have failed prior treatment with Fludara® (fludarabine).

Genasense® Combination Therapy Effective for CLL  -  Feb 20, 2007
Cancer Consultants (press release),Researchers involved in a multicenter trial have reported that the addition of Genasense (oblimersen, Bcl-2 antisense) to Fludara® (fludarabine) and

Oral Formulation Of Fludara® Approved In Japan  -  Jan 29, 2007
Medical News Today (press release),Bayer Schering Pharma AG announced today that the oral formulation of Fludara® for low-grade non-Hodgkin's Lymphoma and mantle cell lymphoma has received

Oral formulation of Fludara approved in Japan  -  Jan 26, 2007
Prdomain Business Register (press release),26 Jan 2007 , Berlin : Bayer Schering Pharma AG announced today that the oral formulation of Fludara® for low-grade non-Hodgkin’s Lymphoma and mantle cell

Addition of Genasense® to Chemotherapy Improves Responses in CLL  -  Feb 16, 2007
Cancer Consultants (press release),According to an article recently published in the Journal of Clinical Oncology, the addition of Genasense® (oblimersen sodium or Bcl2-antisense) to Fludara®

Nektar Appoints Howard W. Robin President and CEO  -  Jan 8, 2007
PharmaLive.com (press release),...may occur after the date of this release. Betaseron and Fludara are registered trademarks of Berlex, Inc. Exubera is a registered trademark of Pfizer Inc.

Nektar Appoints Howard W. Robin President and CEO  -  Jan 8, 2007
Genetic Engineering News (press release),...multiple sclerosis and Fludara(R) (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million.

Diamics Appoints Christine A. Meda as President  -  Jan 5, 2007
Genetic Engineering News (press release),...and as Medical Affairs Director, responsible for clinical trials for their hematological oncology drugs: Fludara, CamPath and Leukine.

Fludara®-Novantrone® Induction and Zevalin® Consolidation Results ...  -  Dec 19, 2006
Cancer Consultants (press release),Researchers from Italy have reported a 100% complete response (CR) rate to induction therapy with oral Fludara (fludarabine) and Novantrone (mitoxantrone)

Rituxan® and Campath® Show Significant Activity in Newly Diagnosed ...  -  Dec 8, 2006
Cancer Consultants (press release),Campath has significant activity for the treatment of patients with CLL who have failed Fludara® (fludarabine) and more recently has been evaluated as

Nipent®, Cytoxan® and Rituxan® Effective for Untreated Poor ...  Oct 30, 2006
One of the most active drug combinations for the treatment of CLL and low-grade NHL is Fludara® (fludarabine), Cytoxan and Rituxan. ... -Cancer Consultants (press release), Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage ...  Oct 9, 2006
Oral fludarabine is currently marketed by Schering AG in the European Union and Canada under the trade name, Fludara(R), for the treatment of relapsed B-cell ... -Drug Newswire (press release), KaloBios Pharmaceuticals Appoints David W. Pritchard as President ...  Oct 12, 2006
...now Bayer). Triton developed Betaseron® for multiple sclerosis (2005 sales exceed $1 billion), and Fludara® for leukemia. He holds ... -Business Wire (press release), Genta's Stock Slides Again As ODAC Turns Back Genasense  Sep 6, 2006
Drugs already approved in the space include Campath (alemtuzumab, from Genzyme Corp.) and Fludara (fludarabine, from Schering AG), and physicians also employ ... -BioWorld Online

Campath® Safe and Active in Patients With CLL After Extensive ...  -  Nov 15, 2006
Cancer Consultants (press release),Campath is currently approved for treatment of patients with B-cell CLL whose disease has stopped responding to alkylating agents and Fludara® (fludarabine)

Rituxan® and Campath® Show Significant Activity in Newly Diagnosed ...  -  Dec 8, 2006
Cancer Consultants (press release),Campath has significant activity for the treatment of patients with CLL who have failed Fludara® (fludarabine) and more recently has been evaluated as

Campath® Safe and Active in Patients with CLL After Extensive ...  -  Nov 13, 2006
Cancer Consultants (press release),...three prior treatment strategies, and 59% of patients had stopped responding to the commonly used chemotherapy agent Fludara® (fludarabine).

Early Reduced-intensity Stem Cell Transplantation Promising for ...  Jul 26, 2006
Patients were treated with Fludara®, Cytarabine, and amsacrine followed by four days of rest, followed by total-body irradiation, cyclophosphamide, and ... -Cancer Consultants

Schering AG raises earnings outlook after strong first half year  Aug 9, 2006
...months of 2006. Net sales of Fludara® and Campath® developed very positively with respective increases of above 20%. Net sales ... -Webbolt Business News

Schering AG Raises Outlook After Strong First Half Year  Jul 25, 2006
...months of 2006. Net sales of Fludara(R) and Campath(R) developed very positively with respective increases of above 20%. Net sales ... -PR Newswire

Reduced Intensity Allogeneic Stem Cell Transplantation in Fludara ...  Jun 22, 2006
Researchers from the Fred Hutchinson Cancer Research Center have reported updated outcomes of 64 patients with Fludara-refractory chronic lymphocytic leukemia ... -Cancer Consultants

Mini Transplants Provide Benefit in Patients with CLL Who Have ...  Jun 22, 2006
...benefit in patients with chronic lymphocytic leukemia who have stopped responding to standard therapies, including the chemotherapy agent Fludara® (fludarabine ... -Cancer Consultants

NDA Filed for Genasense®  Jun 30, 2006
The NDA is seeking approval for the use of Genasense plus Fludara® (fludarabine) and Cytosar® (cyclophosphamide) for treatment of patients with relapsed or ... -Cancer Consultants

View Current Treatment Options for Chronic Lymphocytic Leukemia ...  Jul 7, 2006
MabCampath, Berlex's Campath), which has achieved significant success when used in combination with fludarabine (Schering AG/Berlex's Fludara, generics) in ... -International News Service



Campath® Following Fludara® Improves Responses in Chronic ...  May 2, 2006
...to an early online publication in the Journal of Clinical Oncology, the addition of Campath® (alemtuzumab) following Fludara® (fludarabine) improves ... - Cancer Consultants

Survival Improving for Patients with Stage IV Follicular Lymphoma  Apr 17, 2006
...alternating non-cross resistant regimes with the addition of etoposide, cytarabine, cisplatin and mitoxantrone, the fourth added Fludara® (fludarabine) and ... - Cancer Consultants

Schering AG Q1 Profit Jumps On Pharmaceutical Sales - Update  Apr 26, 2006
While Oncology drug Fludara posted sales increase of 39%, sales of another Gynecology & Andrology therapeutic Microgynon rose 29% for the quarter. ... - Trading Markets

Excellent Start for Schering AG in 2006  Apr 25, 2006
20%. Net sales of Fludara®, Campath® and Bonefos® developed exceptionally well with increases of over 30%, respectively. Furthermore ... - Yahoo! News

Excellent Start for Schering AG in 2006  Apr 26, 2006
20%. Net sales of Fludara(R), Campath(R) and Bonefos(R) developed exceptionally well with increases of over 30%, respectively. Furthermore ... - PharmaLive.com





Nipent®/Cytoxan®/Rituxan® Shows High Activity in Previously ...  Apr 6, 2006
One of the most active drug combinations for the treatment of CLL and low-grade NHL is Fludara® (fludarabine), Cytoxan and Rituxan. ... - Cancer Consultants

Cell Genesys to Present Data From GVAX(R) Cancer Immunotherapy and ...  Mar 30, 2006
5:00 pm EDT) (Abstract ID: 1398) -- An armed oncolytic vector (OV1203) expressing E. coli purine nucleoside phosphorylase (PNP) combined with Fludara(TM) shows ... - Yahoo! News

Addition of Cyclophosphamide to Fludarabine Improves Progression ...  Jan 31, 2006
According to a recent article published in the journal Blood, the addition of cyclophosphamide (Cytoxan®) to fludarabine (Fludara®) improves anticancer ... - Cancer Consultants,

Favrille Reports Fourth Quarter and Year End 2005 Financial ...  Feb 9, 2006
...the last 10 years specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin®, Fludara® and Taxotere ... - Yahoo! News

Favrille Reports Fourth Quarter and Year End 2005 Financial ...  09 Feb 2006
...the last 10 years specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin®, Fludara® and Taxotere ... - Yahoo! News

Addition of Cyclophosphamide to Fludarabine Improves Progression ...  Jan 31, 2006
According to a recent article published in the journal Blood, the addition of cyclophosphamide (Cytoxan®) to fludarabine (Fludara®) improves anticancer ... - Cancer Consultants

Genetic Features Predict Response of Chronic Lymphocytic Leukemia ...  Jan 20, 2006
...among patients with chronic lymphocytic leukemia who are treated with the standard therapeutic combination of Rituxan® (rituximab) and Fludara® (fludarabine ... - Cancer Consultants

Revlimid® Shows Activity in Chronic Lymphocytic Leukemia  Jan 26, 2006
More than 50% of the patients had disease progression following treatment with the commonly used chemotherapy agent Fludara® (fludarabine). ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional